ACE2 and COVID-19: Recently, it was demonstrated in an invitro study that EEOs may show anti-coronavirus disease 2019 (COVID-19) by inhibiting both Angiotensin-converting enzyme II (ACE2) and lipoxygenase enzyme (LOX); the former acts as a functional receptor responsible for host cell entry of the SARS-CoV-2 virus, which causes COVID-19, while the latter was reported to have a pivotal role in the pathophysiology of COVID-19 through induction of pro-inflammatory leukotrienes and cytokines (Ayola-Serrano et al. 2021; Ak Sakallı et al. 2022).